☆ 4.7 Article

Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE (Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC).

JOURNAL OF CLINICAL ONCOLOGY (2020)

Get Full Text
Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 38, Issue 6_suppl, Pages 124-124

Publisher

American Society of Clinical Oncology (ASCO)
DOI: 10.1200/jco.2020.38.6_suppl.124

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.